Sebi fines Biocon, its designated person for violating market norms

Markets regulator Sebi on Wednesday imposed a total fine of Rs 14 lakh on Biocon Ltd and its designated person for violation of market norms. Designated person of the firm, Narendra Chirmule, who was employed with the company as senior vice president-R&D is facing a fine of Rs 5 lakh for trading in the company's securities when the trading window was closed. By doing so, he violated provisions of Prohibition of Insider Trading (PIT) norms. Sebi noted that the trading window was closed by the compliance officer of Biocon from January 1-26, 2019 on account of declaration of quarterly financial results of the company for the quarter ended December 31, 2018, which were announced on January 24, 2019. In accordance with market norms, the company has to notify the particulars of the trading details of the promoter / member of the promoter group /designated person /director, if the value of the securities traded is in excess of Rs 10 lakh, to the stock exchange within 2 trading days of...
19-05-2021

Biocon chief Kiran Mazumdar-Shaw compares COVID vaccination situation in India to arranged marriage

Earlier this week, Mazumdar-Shaw had expressed concern over shortage of COVID-19 vaccines and sought better transparency from the government regarding their availability so that citizens could patiently wait for their turn.
15-05-2021

Biocon perplexed' about Itolizumab not being in Covid protocol

But will ramp up production, says Chief Medical Officer Sandeep Athalye
12-05-2021

Biocon chief expresses concern over Covid-19 vaccine shortage

Biocon Executive Chairman Kiran Mazumdar-Shaw has expressed concern over shortage of Covid-19 vaccines and sought better transparency from the government.
11-05-2021

Covid second wave has hit India 'like a tsunami' says Kiran Mazumdar Shaw

Biocon founder Kiran Mazumdar Shaw attributed the unprecedented spike in coronavirus cases to the recent state elections and religious festivals in the country
06-05-2021
Bigul

BIOCON LTD. - 532523 - Change In The Name And Contact Details Of Key Managerial Personnel Under The Policy For Determination Of Materiality For Disclosures.

Pursuant to Regulation 30 (5) of the SEBI Listing Regulations, the Board at its meeting held on April 28, 2021 has approved amendment in the Policy for Determination of Materiality for Disclosures, and below mentioned Key Managerial Personnel(s) have been authorized to determine materiality of an event or information and make necessary disclosures to the Stock Exchange(s):
03-05-2021

Remdesivir supply issues might ease by third week of May: Biocon's Kiran Mazumdar-Shaw

The sharp surge in COVID-19 cases across has created a massive demand and consequent shortage of medical oxygen and essential drugs.
03-05-2021

Amid weak showing by biosimilars and generics, downgrade pressure on Biocon

Analysts expect ramp-up in biosimilars to be gradual
02-05-2021

Govt should have built safety stock of essential drugs: Kiran Mazumdar-Shaw

The Biocon founder and Executive Chairperson points out that drugs like Remdesivir should be allowed at home as an emergency step
30-04-2021
Next Page
Close

Let's Open Free Demat Account